1998 - 2000 The University of Houston, Main Campus, B.S. in Biology
2002 - 2006 The Universtiy of Texas Medical School at Houston, MD
2006 - June 2010 The University of Texas Medical School at Houston, Resident in Anatomical and Clinical Pathology
July 2010 - July 2011 University of Texas MD-Anderson, Fellow in Surgical Pathology
July 2011 - July 2012 University of Texas MD-Anderson, Combined Cancer Biomarker with Gastrointestinal subspecialty fellowship
2012 Assistant Professor of Pathology, University of Vermont College of Medicine
2013 Zenali M, Overman MJ, Rashid A, Broaddus RB, et. al. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Dec;44(12):2792-8. Epub 2013 Oct 15.
2012 Ordóñez NG, Shen SS, Zenali M, Deavers MT. Melan-A is not a marker of mesothelioma. Appl Immunohistochem Mol Morphol. 2012 Jul. 2010 Zenali M J, Tan D, Li W, Dhingra S, Brown RE. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. Ann Clin Lab Sci. 2010 Spring; 40(2):126-34.
2010 Dhingra S, Tan D, Li W, Zenali M J, Brown RE. Cell Cycle Biology of Fibrolamellar Hepatocellular Carcinoma. Int J Clin Exp Pathol. 2010 Nov 2;3(8):792-7.
2009 Zenali M J, Zhang PL, Brown RE, Morphoproteomic Confirmation of Constitutively Activated mTOR, ERK, and NF-kappaB Pathways in Ewing Family of Tumors, Ann Clin Lab Sci. 2009 Spring; 39(2): 160-6. For a complete list of Maryam Zenali's publications, please visit PubMed.
2009 Burrus, MT, Ramos Y, Zenali M J. An infective cancer – a rare disease with a rarer transformation. UT-Houston Journal of Internal Medicine. Vol 1 (3). Dec 23, 2009